Commonwealth of Pennsylvania Public School Empls Retrmt SYS Buys Shares of 9,524 BioLife Solutions, Inc. $BLFS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in BioLife Solutions, Inc. (NASDAQ:BLFS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 9,524 shares of the medical equipment provider’s stock, valued at approximately $205,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BLFS. State of Wyoming grew its stake in BioLife Solutions by 353.1% during the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 1,490 shares during the last quarter. US Bancorp DE boosted its holdings in BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 1,528 shares in the last quarter. AlphaQuest LLC purchased a new stake in shares of BioLife Solutions during the second quarter worth about $149,000. Strs Ohio purchased a new stake in shares of BioLife Solutions during the first quarter worth about $153,000. Finally, Avantax Advisory Services Inc. increased its holdings in shares of BioLife Solutions by 16.0% during the first quarter. Avantax Advisory Services Inc. now owns 9,077 shares of the medical equipment provider’s stock valued at $207,000 after acquiring an additional 1,250 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Price Performance

NASDAQ:BLFS opened at $26.54 on Friday. The company’s fifty day moving average price is $26.46 and its 200-day moving average price is $24.26. BioLife Solutions, Inc. has a 1-year low of $19.10 and a 1-year high of $29.62. The firm has a market capitalization of $1.28 billion, a P/E ratio of -221.15 and a beta of 1.97.

Insider Buying and Selling at BioLife Solutions

In other news, Director Amy Duross sold 4,523 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $24.51, for a total value of $110,858.73. Following the completion of the transaction, the director owned 25,687 shares of the company’s stock, valued at $629,588.37. The trade was a 14.97% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Casdin Partners Master Fund, L sold 750,000 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $28.55, for a total value of $21,412,500.00. Following the sale, the insider directly owned 5,957,165 shares in the company, valued at approximately $170,077,060.75. This trade represents a 11.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 905,727 shares of company stock worth $25,497,734. Insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BLFS. Zacks Research upgraded shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 7th. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of BioLife Solutions in a research note on Monday. Wall Street Zen raised BioLife Solutions from a “hold” rating to a “buy” rating in a research report on Saturday, November 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.20.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.